•
Jun 30, 2022

Guardant Health Q2 2022 Earnings Report

Reported a revenue increase of 19% year-over-year, driven by growth in clinical and biopharma testing volumes.

Key Takeaways

Guardant Health reported strong Q2 2022 financial results, with revenue reaching $109.1 million, a 19% increase compared to the previous year. The company saw significant growth in clinical and biopharma testing volumes, and received Medicare coverage for Guardant Reveal™.

Revenue of $109.1 million, up 19% year-over-year.

Clinical tests volume increased by 40% year-over-year.

Biopharmaceutical tests volume increased by 65% year-over-year.

Received Medicare coverage for Guardant Reveal™.

Total Revenue
$109M
Previous year: $92.1M
+18.5%
EPS
-$1
Previous year: -$0.61
+63.9%
Gross Profit
$72.4M
Previous year: $62.2M
+16.4%
Cash and Equivalents
$215M
Previous year: $939M
-77.1%
Free Cash Flow
-$135M
Previous year: -$81.3M
+66.1%
Total Assets
$1.85B
Previous year: $2.29B
-19.1%

Guardant Health

Guardant Health

Guardant Health Revenue by Segment

Forward Guidance

Guardant Health continues to expect full year 2022 revenue to be in the range of $460 million to $470 million, representing 23% to 26% growth over full year 2021.